Activated platelet-based inhibition of fibrinolysis via thrombin-activatable fibrinolysis inhibitor activation system

被引:18
|
作者
Suzuki, Yuko [1 ]
Sano, Hideto [1 ]
Mochizuki, Liina [1 ]
Honkura, Naoki [1 ]
Urano, Tetsumei [1 ]
机构
[1] Hamamatsu Univ Sch Med, Dept Med Physiol, Hamamatsu, Shizuoka, Japan
关键词
PLASMA PROCARBOXYPEPTIDASE B; CARBOXYPEPTIDASE-U; PLASMINOGEN ACTIVATION; FACTOR-XIII; THROMBOMODULIN; COAGULATION; LYSIS; TAFI; RESISTANCE; BLOOD;
D O I
10.1182/bloodadvances.2020002923
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Our previous real-time imaging studies directly demonstrated the spatiotemporal regulation of clot formation and lysis by activated platelets. In addition to their procoagulant functions, platelets enhanced profibrinolytic potential by augmenting the accumulation of tissue-type plasminogen activator (tPA) and plasminogen, in vivo in a murine microthrombus model, and in vitro in a platelet-containing plasma dot model. To clarify the role of thrombin-activatable fibrinolysis inhibitor (TAFI), which regulates coagulation-dependent anti-fibrinolytic potential, we analyzed tPA-induced dot lysis times in platelet-containing plasma. Platelets prolonged clot lysis times in a concentration-dependent manner, which were successfully abolished by a thrombomodulin-neutralizing antibody or an activated TAFI inhibitor (TAFIaI). The results obtained using TAFI- or factor XIII-deficient plasma suggested that TAFI in plasma, but not in platelets, was essential for this prolongation, though its cross-linkage with fibrin was not necessary. Confocal laser scanning microscopy revealed that fluorescence-labeled plasminogen accumulated on activated platelet surfaces and propagated to the periphery, similar to the propagation of fibrinolysis. Plasminogen accumulation and propagation were both enhanced by TAFIaI, but only accumulation was enhanced by thrombomodulin-neutralizing antibody. Labeled TAFI also accumulated on both fibrin fibers and activated platelet surfaces, which were Lys-binding-site-dependent and Lys-binding-site-independent, respectively. Finally, TAFIaI significantly prolonged the occlusion times of tPA-containing whole blood in a microchip-based flow chamber system, suggesting that TAFI attenuated the tPA-dependent prolongation of clot formation under flow. Thus, activated platelet surfaces are targeted by plasma TAFI, to attenuate plasminogen accumulation and fibrinolysis, which may contribute to thrombogenicity under flow.
引用
收藏
页码:5501 / 5511
页数:11
相关论文
共 50 条
  • [1] Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin-activatable fibrinolysis inhibitor activation and activated thrombin-activatable fibrinolysis inhibitor activity
    Zhou, X.
    Weeks, S. D.
    Ameloot, P.
    Callewaert, N.
    Strelkov, S. V.
    Declerck, P. J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2016, 14 (08) : 1629 - 1638
  • [2] Thrombin-activatable fibrinolysis inhibitor
    Marx, PF
    CURRENT MEDICINAL CHEMISTRY, 2004, 11 (17) : 2335 - 2348
  • [3] Is there thrombin-activatable fibrinolysis inhibitor in saliva?
    Chopra, S.
    Friman, E.
    Krueger, C. W.
    Antovic, J. P.
    Naimi-Akbar, A.
    BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY, 2020, 58 (09): : E33 - E37
  • [4] Structure of activated thrombin-activatable fibrinolysis inhibitor, a molecular link between coagulation and fibrinolysis
    Sanglas, Laura
    Valnickova, Zuzana
    Arolas, Joan L.
    Pallares, Irantzu
    Guevara, Tibisay
    Sola, Maria
    Kristensen, Torsten
    Enghild, Jan J.
    Aviles, Francesc X.
    Gomis-Rueth, F. Xavier
    MOLECULAR CELL, 2008, 31 (04) : 598 - 606
  • [5] Thrombin-mediated activation of Factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis
    VondemBorne, PAK
    Bajzar, L
    Meijers, JCM
    Nesheim, ME
    Bouma, BN
    JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (10): : 2323 - 2327
  • [6] The effects of hyperglycaemia on thrombin-activatable fibrinolysis inhibitor
    Verkleij, C. J. N.
    Nieuwdorp, M.
    Gerdes, V. E. A.
    Morgelin, M.
    Meijers, J. C. M.
    Marx, P. F.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 392 - 392
  • [7] Characterization of mouse thrombin-activatable fibrinolysis inhibitor
    Marx, PF
    Wagenaar, GTM
    Reijerkerk, A
    Tiekstra, MJ
    van Rossum, AGSH
    Gebbink, MFBG
    Meijers, JCM
    THROMBOSIS AND HAEMOSTASIS, 2000, 83 (02) : 297 - 303
  • [8] Thrombin-activatable fibrinolysis inhibitor in hypothyroidism and hyperthyroxinaemia
    Verkleij, Chantal J. N.
    Stuijver, Danka J. F.
    van Zaane, Bregje
    Squizzato, Alessandro
    Brandjes, Dees P. M.
    Buller, Harry R.
    Meijers, Joost C. M.
    Gerdes, Victor E. A.
    THROMBOSIS AND HAEMOSTASIS, 2013, 109 (02) : 214 - 220
  • [9] The effects of hyperglycaemia on thrombin-activatable fibrinolysis inhibitor
    Verkleij, Chantal J. N.
    Nieuwdorp, Max
    Gerdes, Victor E. A.
    Morgelin, Matthias
    Meijers, Joost C. M.
    Marx, Pauline F.
    THROMBOSIS AND HAEMOSTASIS, 2009, 102 (03) : 460 - 468
  • [10] Enhancement of fibrinolysis by a factor XA inhibitor edoxaban and combination with an inhibitor of activated thrombin-activatable fibrinolysis inhibitor in vitro
    Morishima, Y.
    Kamisato, C.
    Furugohri, T.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 390 - 390